Drug
Opa 15406
Opa 15406: highest development phase Phase 3, developed by Otsuka. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| OPA-15406 NCT07184645 | Phase 3 | Atopic Dermatitis (AD) |
Latest
No recent events.
Follow Opa 15406 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.